CL2016002469A1 - Sulfamidasa modificada y su producción - Google Patents
Sulfamidasa modificada y su producciónInfo
- Publication number
- CL2016002469A1 CL2016002469A1 CL2016002469A CL2016002469A CL2016002469A1 CL 2016002469 A1 CL2016002469 A1 CL 2016002469A1 CL 2016002469 A CL2016002469 A CL 2016002469A CL 2016002469 A CL2016002469 A CL 2016002469A CL 2016002469 A1 CL2016002469 A1 CL 2016002469A1
- Authority
- CL
- Chile
- Prior art keywords
- sulfamidase
- modified sulfamidase
- modified
- production
- dich
- Prior art date
Links
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 title abstract 7
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 title abstract 7
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>En el presente documento, se divulga una sulfamidasa modificada, una composición que comprende una sulfamidasa modificada y métodos de preparación de una sulfamidasa modificada y uso terapéutico de dicha sulfamidasa. Específicamente, la presente divulgación se relaciona con una sulfamidasa modificada que prácticamente no comprende epítopos para los receptores de reconocimiento de glicanos, permitiendo así el transporte de dicha sulfamidasa a través de la barrera hematoencefálica de un mamífero, donde dich</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162996 | 2014-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002469A1 true CL2016002469A1 (es) | 2017-12-15 |
Family
ID=50389999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002469A CL2016002469A1 (es) | 2014-04-01 | 2016-09-30 | Sulfamidasa modificada y su producción |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9982243B2 (es) |
| EP (2) | EP3401325A1 (es) |
| JP (1) | JP6594896B2 (es) |
| KR (1) | KR20160138282A (es) |
| CN (1) | CN106414727A (es) |
| AU (1) | AU2015239126B2 (es) |
| BR (1) | BR112016022333A2 (es) |
| CA (1) | CA2943140A1 (es) |
| CL (1) | CL2016002469A1 (es) |
| CY (1) | CY1120697T1 (es) |
| DK (1) | DK2970413T3 (es) |
| ES (1) | ES2687262T3 (es) |
| HK (1) | HK1231510A1 (es) |
| HR (1) | HRP20181507T1 (es) |
| HU (1) | HUE039691T2 (es) |
| IL (1) | IL247978A0 (es) |
| LT (1) | LT2970413T (es) |
| MA (1) | MA38816B1 (es) |
| MX (1) | MX368947B (es) |
| PH (1) | PH12016501812A1 (es) |
| PL (1) | PL2970413T3 (es) |
| PT (1) | PT2970413T (es) |
| RS (1) | RS57842B1 (es) |
| RU (1) | RU2708026C2 (es) |
| SA (1) | SA516371859B1 (es) |
| SG (1) | SG11201608025QA (es) |
| SI (1) | SI2970413T1 (es) |
| SM (1) | SMT201800511T1 (es) |
| UA (1) | UA120432C2 (es) |
| WO (1) | WO2015150490A1 (es) |
| ZA (1) | ZA201606492B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2970413T3 (en) | 2014-04-01 | 2018-10-15 | Swedish Orphan Biovitrum Ab Publ | Modified sulfamidase and its preparation |
| AU2016329442A1 (en) * | 2015-10-01 | 2018-05-10 | Swedish Orphan Biovitrum Ab (Publ) | Modified lysosomal protein and production thereof |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019145500A1 (en) | 2018-01-26 | 2019-08-01 | Swedish Orphan Biovitrum Ab (Publ) | Method of treatment |
| WO2020047282A1 (en) | 2018-08-29 | 2020-03-05 | University Of Copenhagen | Lysosomal enzymes modified by cell based glycoengineering |
| EP3741867A1 (en) | 2019-05-24 | 2020-11-25 | Swedish Orphan Biovitrum AB (Publ) | Sulfatase activity assay |
| WO2022081765A1 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| DE69724428T3 (de) | 1996-06-07 | 2009-07-23 | Poniard Pharmaceuticals, Inc., Seattle | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20040122216A1 (en) | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| US20090041741A1 (en) * | 2007-03-06 | 2009-02-12 | Saint Louis University | Modified enzyme and treatment method |
| RU2510820C2 (ru) * | 2008-01-18 | 2014-04-10 | Байомарин Фармасьютикал Инк. | Изготовление активных высокофосфорилированных лизосомальных ферментов сульфатаз человека и их применение |
| EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| AU2010366066B2 (en) * | 2010-12-22 | 2016-01-14 | Fondazione Telethon | Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses |
| WO2012177778A1 (en) * | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
| WO2014194427A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted iduronate-2-sulfatase fusion proteins |
| US20140377246A1 (en) | 2013-06-19 | 2014-12-25 | Carol Ann Foundation and International Morquio Organization | Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme |
| DK2970413T3 (en) | 2014-04-01 | 2018-10-15 | Swedish Orphan Biovitrum Ab Publ | Modified sulfamidase and its preparation |
-
2015
- 2015-04-01 DK DK15713502.1T patent/DK2970413T3/en active
- 2015-04-01 WO PCT/EP2015/057256 patent/WO2015150490A1/en active Application Filing
- 2015-04-01 ES ES15713502.1T patent/ES2687262T3/es active Active
- 2015-04-01 RS RS20181119A patent/RS57842B1/sr unknown
- 2015-04-01 SG SG11201608025QA patent/SG11201608025QA/en unknown
- 2015-04-01 RU RU2016140844A patent/RU2708026C2/ru not_active IP Right Cessation
- 2015-04-01 BR BR112016022333A patent/BR112016022333A2/pt not_active Application Discontinuation
- 2015-04-01 PL PL15713502T patent/PL2970413T3/pl unknown
- 2015-04-01 HR HRP20181507TT patent/HRP20181507T1/hr unknown
- 2015-04-01 MA MA38816A patent/MA38816B1/fr unknown
- 2015-04-01 CA CA2943140A patent/CA2943140A1/en not_active Abandoned
- 2015-04-01 JP JP2016560417A patent/JP6594896B2/ja not_active Expired - Fee Related
- 2015-04-01 UA UAA201610956A patent/UA120432C2/uk unknown
- 2015-04-01 EP EP18180516.9A patent/EP3401325A1/en not_active Withdrawn
- 2015-04-01 CN CN201580026957.6A patent/CN106414727A/zh active Pending
- 2015-04-01 SM SM20180511T patent/SMT201800511T1/it unknown
- 2015-04-01 PT PT15713502T patent/PT2970413T/pt unknown
- 2015-04-01 SI SI201530397T patent/SI2970413T1/sl unknown
- 2015-04-01 LT LTEP15713502.1T patent/LT2970413T/lt unknown
- 2015-04-01 AU AU2015239126A patent/AU2015239126B2/en not_active Ceased
- 2015-04-01 HU HUE15713502A patent/HUE039691T2/hu unknown
- 2015-04-01 KR KR1020167030393A patent/KR20160138282A/ko not_active Withdrawn
- 2015-04-01 EP EP15713502.1A patent/EP2970413B1/en active Active
- 2015-04-01 MX MX2016012910A patent/MX368947B/es active IP Right Grant
- 2015-04-01 HK HK17105213.1A patent/HK1231510A1/zh unknown
- 2015-07-22 US US14/806,504 patent/US9982243B2/en active Active
-
2016
- 2016-09-16 PH PH12016501812A patent/PH12016501812A1/en unknown
- 2016-09-19 SA SA516371859A patent/SA516371859B1/ar unknown
- 2016-09-20 ZA ZA2016/06492A patent/ZA201606492B/en unknown
- 2016-09-22 IL IL247978A patent/IL247978A0/en unknown
- 2016-09-30 CL CL2016002469A patent/CL2016002469A1/es unknown
-
2018
- 2018-04-27 US US15/965,597 patent/US20180320152A1/en not_active Abandoned
- 2018-09-24 CY CY181100983T patent/CY1120697T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| GT201700146A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| UY37051A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
| MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
| GT201400297A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CR20150502A (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| PE20151921A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
| LT3169706T (lt) | Antikūnai, besirišantys prie axl | |
| CL2014001853A1 (es) | Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| AR097481A1 (es) | Cocristales energéticos para el tratamiento de una formación subterránea | |
| AR093788A1 (es) | Inmunoterapia con agentes de enlace | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| LT3400019T (lt) | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. |